Oncology

News

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou

Oncology

CDK9 inhibitors: Disrupting cancer cell growth and the treat...

We have made significant strides in cancer treatment in the last decade and a half.

News

EU starts review of Enhertu in HER2-ultra-low breast cancer

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER

News

With FDA okay, AZ takes on MSD in early-stage lung cancer

AstraZeneca has claimed FDA approval for its immunotherapy Imfinzi before and after surgery for non-small cell lung cancer, setting up a contest with MSD's rival Keytruda.

News

AZ gets landmark approval for Imfinzi/Lynparza combo

AstraZeneca has become the first company to get approval for the combination of an immunotherapy with a PARP inhibitor for treating endometrial cancer.

News

Second time lucky at FDA for Citius' lymphoma drug

At the second attempt, the FDA has approved Citius Pharmaceuticals' marketing application for Lymphir, a new version of a lymphoma therapy withdrawn from sale several years ago.

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

CDK9 inhibitors: Disrupting cancer cell growth and the treat...

EU starts review of Enhertu in HER2-ultra-low breast cancer

With FDA okay, AZ takes on MSD in early-stage lung cancer

AZ gets landmark approval for Imfinzi/Lynparza combo

Second time lucky at FDA for Citius' lymphoma drug

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Oncology

Editor's Picks